High throughput drug-screening and safety-testing platforms, that measure human drug toxicity. The platforms integrate:

  • Induced pluripotent stem cells,
  • Cell differentiation technology,
  • Microfluidics,
  • Good manufacturing practices.

We provide 3 platforms:

Induced Pluripotent Stem Cells

Fully reprogrammed Induced Pluripotent Stem Cells which are:

  • Safe to use,
  • Capable of tri-lineage differentiation.

Cell sourcing: We source cells from consented individuals with accompanying clinical information. Following quality control, primary cells are reprogrammed to pluripotency using non-integrative technology.

Microbiological testing: Cell quality control and safety is paramount. We offer PCR based testing solutions for microbial screening.

Pluripotency validation: Cell pluripotency and karyotype stability is examined using state of the art technology.

Differentiation potential: Pluripotent stem cell tri-lineage differentiation is examined using standard two and three dimensional differentiation procedures.

Hepatocytes

To model human exposure, competitors use a plethora of animals or cell lines. These models are unreliable. Frequently, dangerous compounds progress through the drug development process.

Drug induced liver injury often results in irreversible liver failure. It can be fatal or requires a liver transplant. Drug induced liver injury has been the most frequent single cause of safety-related drug marketing withdrawals for the past 50 years: source FDA.

Platform features

  • Unlimited supply of the liver like cells from known genotype & phenotype.
  • Reliable expression and function of prescription drug metabolizing enzymes for screening studies (Cameron et al 2015).
  • Equivalent sensitivity in comparison to cryo-preserved human hepatocytes, within the pharmaceutical industry (Szkolnicka et al 2014 SCTM).
  • Improved cell function and drug sensitivity in response to fluid flow (Rashidi et al 2016, Archives of Toxicology).
  • Industry validation.

Microengineering Platform

Classical cell culture systems and cell lines fail to recapitulate human organ biology.

The three dimensional cell culture in combination with microfluidics offer significant advantages to model human biology ‘in a dish’ and has potential to ‘fill the gap’ that exists between in vitro and in vivo biology.

Platform features

We offer a dedicated, unique and cost-effective microfabrication services for customers in bioreactors and Microsystems. Our team has over 20 years experience in the design, development and application of microfluidic devices and sensors.

  • Custom designs are able to deliver MEMS-enabled devices with a biological focus.
  • Out of the box design and thinking to support all process needs.
  • The ability to rapidly prototype the next generation of bio-MEMS products with when required production ready devices.
  • True flexibility so we can offer low -volume specialty MEMS products at an economic cost.
  • The opportunity to execute the vision for Multiplatform MEMS-enabled devices.

Request a quote 

Fields marked with an * are required